证券代码：000950 证券简称：重药控股 公告编号：2023-054 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 重药控股股份有限公司（以下简称"公司"）已于2023年4月27日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月19日（星期五）下午15:00至16:00时在"重药控股投资者关系"小程序举行2022 年度业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆"重 药控股投资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议，提 前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"重药控股投资者关系"； 参与方式二：微信扫一扫以下二维码： 重药控股股份有限公司 员可能进行调整。） 敬请广大投资者积极参与。 特此公告 重药控股股份有限公司董事会 2023 年 5 月 12 日 投资者依据提示，授权登入"重药控股投资者关系"小程序， ...

证券代码：000950 证券简称：重药控股 编号：2023-006 | --- | --- | --- | |----------------|----------------------------|--------------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 参与单位及人员： | | | | 西南证券：杜向阳、钱彦君 | | | | 德邦证券：张绍辉 | | | | 华夏基金：胥梦缘 | | | | 华泰证券：孔垂岩、王殷杰 | | | | 华安证券：熊智军、权炫瑞 | | | | 兴业证券：王声亮 | | | | 国金证券：王大伟 | | | | 华鑫证券：胡博新 | | | | 大成基金：王敏杰 | | | 活动参与人员 | | | | | 汐泰投资：董函 | | | | 银河证券：张立婧 | | | | 银华基金：孙昊阳、戴方贤 | | | | 中欧基金：任逸 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥19,620,276,794.03, representing a 23.56% increase compared to ¥15,878,655,477.15 in the same period last year[7]. - Net profit attributable to shareholders was ¥166,044,332.35, up 48.40% from ¥111,888,762.43 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥149,020,220.06, a significant increase of 149.12% from ¥59,818,669.95 in the previous year[7]. - The total operating revenue for Q1 2023 was CNY 19,620,276,794.03, an increase of 23.3% compared to CNY 15,878,655,477.15 in the same period last year[36]. - The net profit for Q1 2023 reached CNY 231,764,045.24, representing a 60.7% increase from CNY 144,327,904.72 in Q1 2022[38]. - The total comprehensive income for the period amounted to ¥231,764,045.24, compared to ¥144,327,904.72 in the previous period, reflecting a significant increase[39]. - The net income attributable to the parent company was ¥166,044,332.35, up from ¥111,888,762.43 year-over-year[39]. - Basic and diluted earnings per share both increased to ¥0.10 from ¥0.06 in the previous period[39]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥60,795,703,509.72, reflecting a 6.30% increase from ¥57,191,648,432.88 at the end of the previous year[7]. - The total liabilities as of Q1 2023 amounted to CNY 47,669,938,424.95, an increase from CNY 44,481,256,335.77 in the previous year[36]. - The total liabilities increased, with short-term borrowings reaching 15,105,286,336.39 RMB compared to 14,772,107,320.83 RMB previously[27]. - The company reported a significant increase in other receivables, which rose to 1,331,638,771.54 RMB from 1,131,343,680.69 RMB[27]. Cash Flow - The net cash flow from operating activities was -¥3,093,724,213.10, a 2.07% improvement from -¥3,159,107,305.23 in the previous year[19]. - The cash inflow from operating activities was CNY 18,152,138,655.52, compared to CNY 15,384,982,283.54 in the previous year, marking an increase of 18.2%[32]. - The net cash flow from investing activities decreased by 54.10% year-on-year, primarily due to a reduction in the amount from the sale of stock in International Potash[20]. - The net cash flow from financing activities decreased by 48.49% year-on-year, mainly due to an increase in the repayment of external financing as part of debt structure adjustments[20]. - The company reported a total cash outflow from operating activities of ¥21,245,862,868.62, compared to ¥18,544,089,588.77 in the previous year[43]. - Cash flow from investing activities showed a net inflow of ¥34,079,014.17, compared to ¥74,238,524.35 in the previous year[43]. - Cash flow from financing activities resulted in a net inflow of ¥1,330,850,572.46, down from ¥2,583,847,229.80 year-over-year[43]. Operational Highlights - Accounts receivable increased by 17.03% to ¥33,331,470,842.64, primarily due to concentrated settlements at the end of the previous year and new consolidated entities[12]. - Inventory rose by 4.55% to ¥8,220,329,741.18, driven by business expansion and stockpiling in response to procurement policies[13]. - The company continued to enhance its digital capabilities and organizational structure, leading to improved logistics and marketing capabilities[11]. - The company plans to accelerate its investment and acquisition projects to further expand its market presence[11]. - Research and development expenses increased significantly to CNY 1,497,098.60 from CNY 76,038.11, indicating a focus on innovation[38]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,504[21]. - The largest shareholder, Chongqing Pharmaceutical Health, holds 38.14% of the shares, totaling 664,900,806 shares[21]. Financial Expenses - The financial expenses increased by 25.37% to ¥328,473,998.37, mainly due to the issuance of asset securitization products[16]. - The company’s financial expenses rose to CNY 328,473,998.37 from CNY 262,001,662.52, reflecting increased borrowing costs[38]. Audit and Reporting - The company did not undergo an audit for the first quarter report[44]. - The report was released by the board of directors on April 27, 2023[45].

Financial Performance - The company's operating revenue for 2022 was ¥67.83 billion, an increase of 8.49% compared to ¥62.52 billion in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥952.28 million, a decrease of 5.29% from ¥1.01 billion in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥875.40 million, an increase of 5.17% from ¥832.39 million in 2021[24]. - The net cash flow from operating activities was ¥285.83 million, up 14.26% from ¥250.16 million in 2021[24]. - Total assets at the end of 2022 were ¥57.19 billion, a 15.07% increase from ¥49.70 billion at the end of 2021[25]. - The company's basic earnings per share for 2022 was ¥0.55, down 5.17% from ¥0.58 in 2021[24]. - The weighted average return on equity for 2022 was 9.30%, a decrease of 1.48% from 10.78% in 2021[24]. - The total revenue for the reporting period reached 67.829 billion yuan, marking an overall increase of 8.49%[63]. - The pharmaceutical segment accounted for 84.20% of total revenue, with a year-on-year increase of 5.69%[66]. - The medical device segment achieved revenue of 9.514 billion yuan, growing by 26% year-on-year[69]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.6 CNY per 10 shares to all shareholders, with no stock bonus[4]. - The proposed cash dividend is ¥0.6 per 10 shares (including tax), with a total cash dividend amounting to ¥104,602,040.22, representing 100% of the distributable profit[174]. - The total number of shares for the dividend distribution is 1,743,367,337 shares, which will be adjusted if there are changes in the total share capital before the distribution[176]. - The company has a positive distributable profit of ¥106,164,101.60 available for distribution to shareholders[174]. - The independent directors have expressed their agreement with the profit distribution proposal, confirming its compliance with legal and regulatory requirements[173]. Business Strategy and Market Position - The company is focusing on digital healthcare services and expanding its professional pharmacy layout, targeting high-quality and specialized pharmaceutical services[35]. - The company is transitioning towards becoming a comprehensive supply chain service provider, covering 31 provinces and providing efficient services to various healthcare institutions[42]. - The company is actively optimizing its retail pharmacy network and accelerating the construction of prescription outflow platforms to capture more market share[39]. - The company is implementing a strategy of integrating wholesale and retail operations to enhance its market presence and service quality[45]. - The company aims to achieve over 100 billion RMB in revenue by 2025 as part of its "14th Five-Year" strategic plan[116]. - The company plans to establish over 1,000 retail pharmacies, focusing on DTP prescription pharmacies and community health pharmacies in the Sichuan-Chongqing region[122]. Research and Development - The company is actively investing in pharmaceutical R&D, emphasizing innovative development and collaboration with domestic and international research institutions[53]. - The company invested 5% of its revenue in R&D, focusing on innovative platforms and achieving over 60% of products with dual submissions in China and the U.S.[74]. - Research and development expenses increased by 25% in 2022, totaling 500 million RMB, to enhance product innovation[147]. - New product development is underway, with a focus on innovative pharmaceutical solutions to meet market demands[141]. Risk Management and Compliance - The company acknowledges potential risks related to industry competition, management, market conditions, and national policies[4]. - The company emphasizes adherence to legal and regulatory frameworks, ensuring the protection of shareholder rights and corporate governance[162]. - The company is implementing a comprehensive risk management system to ensure quality control and financial oversight[123]. Corporate Governance - The company has established an independent financial accounting system and maintains financial independence from its controlling shareholders[132]. - The company held six shareholder meetings in 2022, with participation rates ranging from 63.66% to 80.28%[134]. - The company has a clear commitment to uphold the legal obligations of shareholders and will not interfere with the business activities of the listed company[198]. - The company has established a governance structure that allows independent decision-making by the board and management[198]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 13,809, with 62 at the parent company and 13,747 at major subsidiaries[166]. - The company is committed to enhancing employee training through various programs, including "Mini MBA" and "New Employee Training"[169]. - A total of 20.85 million training sessions were conducted across the company and its subsidiaries in 2022[169]. Acquisitions and Investments - The company made significant equity investments, including a ¥245,195,000 acquisition for an 80% stake in Hunan Jiameng Pharmaceutical[102]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[141]. - The company has expanded its market presence through non-controlling mergers, including Chongqing Pharmaceutical Group Hunan Co., Ltd., enhancing the medical device distribution market[113]. Social Responsibility - The company actively participated in social responsibility initiatives, contributing a total of 44,200 yuan to consumption poverty alleviation efforts[195]. - The company issued four phases of rural revitalization notes, raising a total of 900 million yuan, part of which was used for drug procurement in 18 poverty alleviation areas[194].

Group 1: Company Development Overview - The company was restructured and listed in 2018, gradually evolving from a regional pharmaceutical distribution enterprise to a national group in the industry, covering all 31 provinces, municipalities, and autonomous regions in China by Q3 2022 [2][3] - The company has over 200 subsidiaries and has achieved a compound annual growth rate (CAGR) of approximately 27% in revenue over the past five years [2][3] - The proportion of sales outside the home region increased from 34% to 57% in the last five years, indicating effective implementation of the national layout strategy [2][3] Group 2: Strategic Goals - The company's "14th Five-Year Plan" aims for a sales scale exceeding 100 billion yuan, driven by both organic growth and external expansion [3] - The strategy includes completing layouts in 300 prefecture-level cities and enhancing capabilities in marketing, supply chain, IT, and auxiliary diagnosis [3] Group 3: Business Segmentation and Performance - The company operates in four segments: pure sales (69.4%), distribution (17.4%), terminal (9.5%), and retail (3.7%), with year-on-year growth rates of 8%, 11%, 27%, and 16% respectively as of Q3 2022 [3] - Sales of pharmaceuticals and medical devices account for 85.5% and 14.5% of total sales, respectively, with traditional Chinese medicine and narcotic drugs making up about 3% and 1.4% of pharmaceutical sales [3] Group 4: Industrial Layout and R&D - The company has entered the pharmaceutical manufacturing sector through equity participation, notably in Chongqing Yaoyou Pharmaceutical Co., which is a national high-tech enterprise [4] - The company is enhancing collaboration with domestic and international R&D institutions to develop new products that align with its strategic goals [4]

Group 1: Company Overview - Chongqing Pharmaceutical Holdings is a large modern pharmaceutical distribution enterprise serving the entire pharmaceutical industry chain, involved in pharmaceutical research and development, medical device production, and investment in pharmaceutical industry collaboration [2][3] - The company operates under the Chongqing Pharmaceutical (Group) Co., Ltd., established in 1950, and is one of the few national wholesale enterprises for anesthetics and first-class psychotropic drugs in China [2][3] Group 2: Strategic Planning - The company's 14th Five-Year Plan aims for high-quality development, targeting sales exceeding 100 billion yuan by 2025, with a focus on "internal growth and external expansion" [3] - The strategic goal includes establishing a presence in 300 prefecture-level cities and enhancing capabilities in marketing, supply chain, IT, and auxiliary diagnosis [3] Group 3: Business Model Advantages - The integrated wholesale and retail model reduces operational costs and enhances supply chain advantages, facilitating the introduction of various drug categories into retail channels [3][4] - The company has established over 100 specialized pharmacies nationwide, promoting a new business model for prescription drug sales through internet hospitals [4] Group 4: Mergers and Acquisitions - The company's mergers and acquisitions during the 13th Five-Year Plan have expanded its national network and increased profitability, with profits from outside Chongqing rising from approximately 35% in 2018 to about 60% by 2021 [4] Group 5: Logistics and Supply Chain - The company boasts an advanced logistics distribution system, focusing on pharmaceutical supply chain services, with multiple distribution centers established in various provinces [4][5] - Chongqing Pharmaceutical Group's logistics subsidiary aims to create the largest third-party distribution and pharmaceutical logistics business in the western region [5]

Group 1: Company Development Strategy - The company aims for high-quality development during the 14th Five-Year Plan, focusing on optimizing industrial structure and accelerating innovation, targeting sales exceeding 100 billion CNY by 2025 [3] - The strategic guidance includes "One Thousand, Two Doubles, Three Hundreds Cities, Three Transformations, Four Capabilities, Five Troops," with plans to establish a presence in 300 prefecture-level cities nationwide [3] - The company will enhance its service capabilities in marketing, supply chain, IT, and auxiliary diagnosis, focusing on five key profit-contributing strategic areas: medical devices, professional pharmacies, traditional Chinese medicine health products, third-party storage, and emerging businesses [3] Group 2: Business Segments Development - The medical device segment is the second-largest product category, with over 110 companies engaged in this business, establishing long-term distribution relationships with international manufacturers [3] - The retail segment operates mainly through self-operated pharmacies and franchise pharmacies, with over 800 retail stores across 19 provinces, focusing on integrated wholesale and retail strategies [3][4] - The traditional Chinese medicine business is a key development area, with plans to build top-tier TCM clinics and improve distribution services for TCM decoction pieces [4] Group 3: Financial Management and Risks - The company is one of the few national wholesalers of narcotic and psychotropic drugs, with a stable sales network covering all 31 provinces and regions [4] - Accounts receivable are significant due to the nature of the business, primarily involving public hospitals, but the company maintains a low risk of collection [4] - Measures to improve cash flow include strengthening accounts receivable management and enhancing procurement management [4] Group 4: Future Growth and Mergers - The company plans to continue pursuing mergers and acquisitions during the 14th Five-Year Plan, focusing on high-quality targets and expanding its commercial wholesale investments in blank areas [5] - There will be an emphasis on acquiring and strategically cooperating in medical devices, retail chains, and traditional Chinese medicine sectors to enhance national network coverage [5]

Group 1: Fraud Warning - The company has never launched any financial management apps or crowdfunding activities, nor authorized any individuals or entities to conduct such businesses [2] - Investors are advised to rely solely on information disclosed through the company's official channels, including the China Securities Regulatory Commission and the official website [2] Group 2: Company Information - The registered name of the company is Chongqing Pharmaceutical Holding Co., Ltd., with the official website being www.cqphar.com [2] - The company's investor reception hotline is 023-63910671 [2] Group 3: Legal Action - The company strongly condemns any fraudulent activities impersonating the company or its subsidiaries and reserves the right to take legal action against such entities [2] - Investors are urged to report any impersonation incidents to local law enforcement [2]

Group 1: Strategic Planning - The company's "14th Five-Year" strategic plan aims for revenue exceeding 100 billion by 2025, with a focus on dual internal and external growth [2] - The plan includes a nationwide commercial network covering over 300 regions, emphasizing integrated retail and wholesale, product diversification, and digital business [2] - Key capabilities targeted include marketing solutions, supply chain solutions, IT solutions, and clinical support solutions [2] Group 2: Business Segments - The medical device segment is a crucial part of the business, with goals to establish a nationwide network and achieve scale effects during the "14th Five-Year" period [3] - The company aims to transition to a service-driven and technology-driven medical device service provider, enhancing its competitive position in the market [3] - The company plans to leverage regional advantages in areas like Guizhou and Sichuan to gain national influence in specific segments such as orthopedics and maternal and child health [3] Group 3: Logistics and Supply Chain - The company has a sophisticated logistics distribution system focused on pharmaceutical supply chain services, with multiple distribution centers across various provinces [3][4] - The logistics company manages over 90,000 square meters of central warehouse space in Chongqing, adhering to GSP and international storage standards [4] - The central distribution center located in the Chongqing Free Trade Zone offers advantages such as local customs clearance [4] Group 4: Investor Relations Activity - The investor relations activity on January 11, 2023, involved discussions on the company's strategic planning and business performance [2][5] - No undisclosed significant information was leaked during the activity, ensuring compliance with disclosure regulations [5]